Patent Law

The Practising Law Institute is hosting a seminar with the above title in New York City and San Francisco (Live Webcast) on September 11, 2008 and October 15, 2008, respectively.

Pharmaceutical and biotech patent law is an important and rapidly changing practice area. Technological innovation, Federal Circuit appellate oversight, Congressional action and Supreme Court decisions have all driven significant changes in the law. Several different perspectives on many of the most pressing issues will be offered from experienced in-house and outside counsel, Federal District Court judges who have tried patent cases, and attorneys from the PTO?s Office of the Solicitor.

What You Will Learn

• The patentability of active pharmaceutical ingredients and the impact of KSR v. Teleflex
• Issues relating to pharmaceutical and biotech transactions, including due diligence, practical considerations and patent misuse and antitrust considerations
• Patent issues impacting research tools used in drug discovery and development
• Testing the limits of patentable biotech and pharmaceutical subject matter
• How the PTO helps to shape the development of Federal Circuit and Supreme Court precedent
• Perspectives on trying pharmaceutical and biotech patent cases

More details and registration information are available here.

Co-Chairs

David K. Barr, Kaye Scholer LLP
Daniel L. Reisner, Kaye Scholer LLP

Speakers

Hon. William G. Bassler (Ret.), Senior District Judge, JAMS
Thomas Krause, Associate Solicitor, United States Patent and Trademark Office, Solicitor's Office
Hon. John C. Lifland (Ret.), District Judge, JAMS
Michael M. Shih, Director, Business Development, Eisai Inc.
Aaron Stiefel, Kaye Scholer LLP
Errol B. Taylor, Milbank, Tweed, Hadley & McCloy LLP
Jennifer A. Tegfeldt, Director, Business Initiatives and Strategy, Genzyme Corporation
Roy F. Waldron, Assistant General Counsel, Pfizer Inc.

Program Attorney

John M. Mola, Practising Law Institute